Cardiovascular Systems Inc

Cardiovascular Systems — Corporate Update (September 2019)

24 slides from Cardiovascular Systems's corporate update, Sep 26, 2019

  1. Slide 1: Product Pipeline Update

    Cardiovascular Systems, Inc. Product Pipeline Update September 26, 2019 ©2019 Cardiovascular Systems, Inc. All Rights Reserved.

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Introduction

    Introduction Scott R. Ward, Chairman, President & Chief Executive Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 3

  4. Slide 4: Driving Sustainable Growth

    Driving Sustainable Growth Broaden Our Value Streams Financial Goal: FY19-FY23 CAGR of 15% - 18% Revenue of $435M - $500M in FY23 Grow and Protect Innovation Drives Global Expansion Accelerates the Core Business Incremental Growth Growth of Core Business Sustain Market Leadership Launch 20+ New Prod

  5. Slide 5: Fiscal 2019 Revenue Growth of 14.3%

    Fiscal 2019 Revenue Growth of 14.3% $248 Million New Product Revenue $3.9 million Core OAS Revenue $236.2 million Drivers 10% increase Sapphire II 1.0 mm PTCA Teleport Microcatheter Zilient Peripheral Guidewire International Revenue $7.9 million Drivers Launched OAS in 10 New countries Product, Over

  6. Slide 6: Portfolio Update

    Portfolio Update Rhonda J. Robb, Chief Operating Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 6

  7. Slide 7: Current Market Dynamics Favor Innovation

    Current Market Dynamics Favor Innovation Large Under-Served and Under-Treated Disease States Peripheral Artery Disease Coronary Artery Disease Growing proportion of coronary Significantly under-diagnosed and interventions represented by complex under-treated patient populations or complex high-risk

  8. Slide 8: Diversification Accelerates Growth

    Diversification Accelerates Growth Broadens Value Streams CSI’s Addressable Markets (US) ~$3.7B Hemodynamic Support Interventional Support Devices Atherectomy Portfolio expansion will drive a >4X increase in CSI’s addressable market $650M FY19 FY23 • Millennium Research Group (2018 December) Medtech

  9. Slide 9: Differentiated Pipeline of Key Value Drivers

    Differentiated Pipeline of Key Value Drivers Supports Diversified and Sustainable Growth FY19 FY23 FY23 Growth / Value Drivers Portfolio Market Market TAM FY20 FY21/22 FY23+ • CAD ViperWire Advance with • Next gen Coronary OAS Flex Tip • ECLIPSE • PAD Directional Atherectomy • Peripheral Diamondback

  10. Slide 10: Peripheral

    Peripheral ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 10

  11. Slide 11: Radial is a Core Competitive Advantage

    Radial is a Core Competitive Advantage Enabling a Complete Peripheral Intervention from the Radial Artery Launched Q2 FY19 Launched Q1 FY19 Expected Launch Early FY21 Exclusive route of access for CSI complementary to tibial/pedal Extended length Extended length Radial Expansion in portfolio of Exch

  12. Slide 12: Supporting Complete Leg Revascularization

    Supporting Complete Leg Revascularization Exchangeable Series with GlideAssist® – Our Most Advanced OAS on the Market GlideAssist to facilitate tracking, repositioning and removal of OAD through challenging anatomy Ease-of-Use Enhancements to Handle: Backloadable system facilitating easier wire exch

  13. Slide 13: Exchangeable is a Competitive Advantage

    Exchangeable is a Competitive Advantage Exchangeable Series OAS live case, including feature of Teleport® Microcatheter and Zilient® Guidewire Dr. Fadi Saab, Amputation Prevention Symposium, August 14, 2019 13

  14. Slide 14: Compelling Clinical Evidence Supporting Atherectomy

    Compelling Clinical Evidence Supporting Atherectomy; OAS Short- and Long-Term Safety Atherectomy provides a benefit for CLI Surgical bypass-first treatment was patients—in this study, there were lower associated with worse amputation free rates of 4-year major amputation and survival (AFS) compared

  15. Slide 15: Directional Atherectomy

    Directional Atherectomy Expanding the Treatment Options for Soft and Fibrotic Mixed Plaque Lesions Broaden value streams in a $300M-$400M existing ATK atherectomy market Extend CSI’s peripheral atherectomy toolkit to Deliver novel cutter design to improve lesion entry, engagement, and treatment, wit

  16. Slide 16: WIRION Embolic Protection System

    WIRION® Embolic Protection System Supporting Our Commitment to Complex Patients Protecting Patients During PVIs Share-Taking Differentiated Technology Embolic debris can be associated with all types of peripheral vascular intervention procedures EPDs are typically used when treating vessels located

  17. Slide 17: Coronary

    Coronary ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 17

  18. Slide 18: Near-Term Expansion of the Complex Coronary Toolkit

    Near-Term Expansion of the Complex Coronary Toolkit Drives Incremental Revenue Opportunity Per Case Launched FY19 Launched FY19 Expected Launches FY20 Adding Essentials of the Complex PCI Toolkit • Sapphire SC II PRO 1.0-4.0mm • Sapphire SC II PRO 1.0mm OTW • Sapphire NC Plus 2.0-4.0mm • Sapphire NC

  19. Slide 19: ECLIPSE Trial

    ECLIPSE Trial Generating Level One Evidence to Impact Guidelines Patients with Severely 2000 Primary Endpoints Calcified Lesions Randomize 1:1 Orbital Atherectomy Strategy Conventional Angioplasty Strategy ~500 subjects in OCT cohort 1.25 mm Classic Crown followed by Conventional and/or specialty ba

  20. Slide 20: Percutaneous Ventricular Assist Device (pVAD) System

    Percutaneous Ventricular Assist Device (pVAD) System Multi-Generational Platform Highly Synergistic with Our Strategy and Competency Generation 1 Overview Entering a High Growth pVAD Market* $1,800 $1,500 16% CAGR $1,200 $900 • Leverages CSI core Millions $ $600 competency in motor control and spinn

  21. Slide 21: Closing Remarks

    Closing Remarks Scott R. Ward, Chairman, President & Chief Executive Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 21

  22. Slide 22: Platform for Growth

    Platform for Growth Maintain focus on current customer, vessel preparation and procedure support Organic growth and opportunistic portfolio management ~$250M Gross margins in the range of 78%-80% in FY19-FY23 FY21 R&D Investments R&D investments increase to 14%-17% of revenues in FY21 Launch 20 new

  23. Slide 23: Driving Sustainable Long-Term Growth

    Driving Sustainable Long-Term Growth Product Launches FY19 - FY23 Revenue Growth FY19 FY20 FY21-FY23 5 - Year CAGR: 15% – 18% • Radial OAS • Exchangeable OAS • Radial toolkit • Peripheral • Next generation • Scoring balloons Guidewires OAS with • WIRION embolic $340M - $350M • ViperCath XC GlideAssi

  24. Slide 24: Creating Shareholder Value

    Cardiovascular Systems, Inc. Creating Shareholder Value Financially Strong Leveraging a A Compelling Creating with the Team and Strong Core Business Growth Strategy Competitive Advantage Talent to Win Sustaining double digit Improving outcomes for Driving market leading Highest quality growth comple

Cardiovascular Systems — Corporate Update (September 2019) on 6ix